FDA to decide on Rocket Pharmaceuticals' gene therapy KRESLADI™

The U.S. Food and Drug Administration (FDA) is expected to deliver its decision on March 28 for Rocket Pharmaceuticals' KRESLADI™, a gene therapy developed for LAD-I. This rare disease affects children, with a high mortality rate before the age of two. Currently, the only treatment option is a bone marrow transplant, while KRESLADI™ aims to correct the underlying cause of the condition.

Clinical trial data for KRESLADI™ has shown significant promise. A Phase 1/2 study reported 100% overall survival at 12 months post-infusion for all enrolled patients. All primary and secondary endpoints were met, with no serious adverse events related to the treatment reported. These results have already influenced Rocket Pharmaceuticals' stock, which rose 23.1% on the day the FDA accepted the resubmission of the Biologics License Application (BLA).

A potential approval for KRESLADI™ could have broad implications for the regenerative medicine sector. The therapy holds multiple FDA designations for accelerated review, including Rare Pediatric Disease and Fast Track status. The global regenerative medicine market is projected for substantial growth, and a successful approval could boost investor confidence in gene therapies.

If approved, Rocket Pharmaceuticals may also receive a Priority Review Voucher, potentially valued at over $100 million. This tradable asset could provide significant financial runway for the company to advance its pipeline, including a late-stage program for Danon disease. The FDA's decision on March 28 is critical not only for the patients awaiting treatment but also for the future investment and development in gene therapy.